March 24, 2023 4:48pm

Shaking-off some of the fear and uncertainty

Share pricing past: Avrobio (AVRO) closed up +$0.085 to $0.97– repeating it’s not-so-long-ago past of being below Nasdaq’s $1.00 bid price requirement

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about - truth!  

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

The week in review …


If I have learned one thing as a former research analyst in a venture and public fund, operating executive, adjunct (MBA) business school professor now a journalist; it is that your life and your portfolio are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +132.28 points (+0.41%), the S&P closed UP +22.27 points (+0.56%) while the Nasdaq closed UP +36.56 points (+0.31%)

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Stock indexes closed up even after selling pressure Friday, weighed down by weakness in European financial stocks.

Also, as investors fled from risky assets on growing concerns that a contagion in the banking sector had not been fully confined.

For the week, the Dow gained +0.04%, S&P 500 +1.4% and the Nasdaq has gained roughly +1.6%.

Economic Data Docket: Demand for long-lasting goods such as appliances, TVs and computers fell more than expected in February, the Commerce Department reported Friday. Durable goods orders declined 1% for the month, more than the estimate for a 0.3% decline though less than the 5% plunge in January. Excluding transportation, new orders were unchanged, while orders less defense fell 0.5%.

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences

  • Friday’s advance/decline line opened negative at 4 up/ 30 down and 1 flat, stayed negative with 11 up/ 22 down and 2 flats at the mid-day, ending with a positive close of 19/15 and 1 flat
  • Thursday’s advance/decline line opened positive at 24 up/ 8 down and 3 flats, flipped negative with 11 up/ 23 down and 1 flat at the mid-day, ending with a positive close of 20/15 and 0 flat
  • Wednesday’s advance/decline line opened negative at 5 up/ 29 down and 1 flat, stayed negative with 4 up/ 31 down and 0 flat at the mid-day, ending with a negative close of 3/32 and 0 flat
  • Tuesday’s advance/decline line opened positive at 23 up/ 10 down and 2 flats, stayed positive with 21 up/ 13 down and 1 flat at the mid-day, ending with a positive close of 21/13 and 1 flat
  • Monday’s advance/decline line opened negative at 11 up/ 22 down and 2 flats, stayed negative with 10 up/ 22 down and 3 flats at the mid-day, ending with a negative close of 13/21 and 1 flat

 

52-week low:

·         Avrobio (AVRO) at $0.96 – back under $1.00 repeating the past

·         Homology Medicine (FIXX) at $0.91

·         Editas Medicine (EDIT) at $7.43

·         Prime Medicine (PRME) at $11.31

·         Precigen (PGEN) at $0.95

·         Sangamo Therapeutics (SGMO) at $1.67

 

RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting … https://www.regmedinvestors.com/articles/12843 - 28 of 35

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB was up +1.22% and the XBI was up +0.66%
  • Thursday, the IBB was UP +0.90% and the XBI was up +0.78%
  • Wednesday, the IBB was down -2.14% and the XBI was down -3.79%
  • Tuesday, the IBB was up +0.12% and the XBI was down -1.03%
  • Monday, the IBB was up +1.08% and the XBI was up +0.37%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was down -0.51 points or -2.26% at 22.10
  • Thursday was up +0.17 points or +0.76% at 22.43
  • Wednesday was up +0.85 points or +3.98% at 22.23
  • Tuesday was down -2.59 points or -10.72% at 21.56
  • Monday was down -1.38 points or -5.41% at 24.13

 

Closing Down (10 of 15):

  • Alnylam Pharmaceuticals (ALNY -$0.51 after Thursday’s +$0.73),
  • Prime Medicine (PRME -$0.37 after Thursday’s -$0.82 after Wednesday’s -$0.88, Tuesday’s +$0.38 and Monday’s +$0.61),
  • MiMedx (MDXG -$0.15),
  • Regenxbio (RGNX -$0.13after Thursday’s +$0.25 and Wednesday’s -$1.23),
  • Voyager Therapeutics (VYGR -$0.11),
  • Solid Biosciences (SLDB -$0.09),
  • Mesoblast (MESO -$0.06 after Thursday’s -$0.05, Wednesday’s +$0.12 and Tuesday’s +$0.20),
  • Sangamo Therapeutics (SGMO -$0.04 after Thursday’s -$0.06),
  • Brainstorm Cell Therapeutics (BCLI -$0.035),
  • Chinook Therapeutics (KDNY -$0.03 after Thursday’s +$0.73),

Flat (1):

  • Biostage (OTCQB: BSTG)

Closing Up (10 of 19):

  • Intellia Therapeutics (NTLA +$1.12),
  • Ultragenyx (RARE +$0.69 after Thursday’s -$0.29, Wednesday’s -$1.06, Tuesday’s -$0.66 and Monday’s +$0.47),
  • Sage Therapeutics (SAGE +$0.46 after Thursday’s +$0.42, Wednesday’s -$1.26, Tuesday’s -$0.69 and Monday’s +$1.23),
  • Ionis Pharmaceuticals (IONS +$0.33 after Thursday’s -$1.67),
  • Caribou Biosciences (CRBU +$0.33),
  • AxoGen (AXGN +$0.30),
  • CRISPR Therapeutics (CRSP +$0.29 after Thursday’s -$0.40, Wednesday’s +$1.52, Tuesday’s +$0.60 and Monday’s -$1.28)
  • Vericel (VCEL +$0.16 after Thursday’s +$0.52, Wednesday’s -$2.11, Tuesday’s +$0.46 and Monday’s +$0.63),
  • Fate Therapeutics (FATE +$0.16),
  • Avrobio (AVRO +$0.085 after Thursday’s -$0.34),

 

Q1/23 – March

  • Friday closed positive with 19 incliner, 15 decliners and 1 flat
  • Thursday closed positive with 20 incliner, 15 decliners and 0 flat
  • Wednesday closed negative with 3 incliner, 32 decliners and 0 flat
  • Tuesday closed positive with 21 incliner, 13 decliners and 1 flat
  • Monday closed negative with 13 incliner, 21 decliners and 1 flat

 

The BOTTOM LINE: I try to keep it simple … and short!

The cell and gene therapy sector equities closed up after being dragged down on Thursday’s while late session trading on Friday pushed “our’ universe to the upside.

A tough week as the roller-coaster of share pricing fell into the abyss to climb out late in session on Friday.

The rush of Q4 and FY22 earnings to release is on … 28 of my 35 covered have reported.

Upcoming Q4 earnings reporting will present challenges to share pricing.

·         2 – Thursday – Avrobio (AVRO) and Solid Biosciences (SLDB)

·         Seven (7) more releases forthcoming of my 35 covered companies

·         Brainstorm Cell Therapeutics (BCLI) 3/30 - Thursday

WHY (?) do I keep posting, so investors can get a daily update of the sector's share pricing and some individual companies TRUTHS while electronic trading chews on our portfolio edges.

Remember, there are four (4) phases of the stock cycle: accumulation; markup; distribution; and markdown.

As I have stated, “What goes up with ceremony, goes down with disdain followed by the opposite effect.”

I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.

The NO spin zone!

Biostage (OTCQB: BSTG) – still pumping the volume and TRYING to promote the share price!!

Friday closed flat with 15 shares traded  <3-month average volume = 1,728 shares>

·         Question: Review the number of shares traded … is OTCQB: BSTG a Ponzi scheme (with their pump/promote buy and sell agenda) as shares are bought to replace those sold??

·         Let’s also welcome a NEW accounting firm – the fourth (4th) in five (5) years. When will they resign …??

·         Where is the SEC??

·         NEW Auditors must consider whether there is substantial doubt about a company’s ability to continue as a going concern, an assessment of the company’s viability over the next year.

·         Continuing as an “going concern”!

 

My question that resounds, that should be asked is how many companies are at the end of sentiments …  leash?

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.